

ORIGINAL

sfw

Attorney Docket No. LeA 36 230

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hendrix, et al.

Group No.:

Serial No.: 10/525,115

Examiner:


Filed: 18 February 2005

For: Phenyl-Substituted Pyrazolopyrimidines

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 11 April 2006


Gil Cunha

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.


IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed within three months of the filing or nationalization of this application, or before the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,



Susan M. Pellegrino
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Reg. No.: 48,972

Telephone: (203) 812-6450

Date: 11 April 2006

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 4 |
|-------|---|----|---|

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/525,115 |
| Filing Date | 18 February 2005 |
| First Named Inventor | Hendrix, et al. |
| Art Unit | |
| Examiner Name | |
| Attorney Docket Number | LeA 36 230 |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | |
| | F1 | CH 396,924 | 08-15-1965 | CIBA AG | |
| | F2 | CH 396,925 | 08-15-1965 | CIBA AG | |
| | F3 | CH 396,926 | 08-15-1965 | CIBA AG | |
| | F4 | CH 396,927 | 08-15-1965 | CIBA AG | |
| | F5 | DE 2,408,906 | 02-25-1974 | Chemische Fabrik von Heyden GmbH | |

| | | | |
|-----------------------|------------------|--------------------|------------|
| Examiner Signature | /Jeffrey Murray/ | Date Considered | 03/17/2008 |
|-----------------------|------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|------------------|------------------------|------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/525,115 | | |
| | | Filing Date | 18 February 2005 | | |
| | | First Named Inventor | Hendrix, et al. | | |
| | | Art Unit | | | |
| Examiner Name | | | | | |
| Sheet | 2 | of | 4 | Attorney Docket Number | LeA 36 230 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | R1 | WEI, et al., Molecular and Pharmacological Analysis of Cyclic Nucleotide-Gated Channel Function in the Central Nervous System, Progress in Neurobiology, vol. 56, 1998, pp. 37-64 | |
| | R2 | FISHER, et al., Isolation and Characterization of PDE9A, A Novel Human cGMP-specific Phosphodiesterase, Journal of Biological Chemistry, vol. 273, no. 25, 1998, pp. 15559-15564 | |
| | R3 | GUIPPONI, et al., Identification and Characterization of a Novel Cyclic Nucleotide Phosphodiesterase Gene (PDE9A) That Maps to 21q22.3: Alternative Splicing of mRNA Transcripts, Genomic Structure and Sequence, Hum Genet, vol. 103, 1998, pp. 386-392 | |
| | R4 | SONDERLING, et al., Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases, Journal of Biological Chemistry, vol. 273, no. 25, pp. 15553-15558 | |
| | R5 | ANDREEVA, et al., Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain, Journal of Neuroscience, vol. 21, no. 22, 2001, pp. 9068-9076 | |
| | R6 | MARTINS, et al., Purification and Characterization of a Cyclic GMP-stimulated Cyclic Nucleotide Phosphodiesterase from Bovine Tissues, Journal of Biological Chemistry, vol. 257, no. 4, 1982, pp. 1973-1979 | |
| | R7 | FRANCIS, et al. Characterization of a Novel cGMP Binding Protein from Rat Lung, Journal of Biological Chemistry, vol. 255, no. 2, 1980, pp. 620-626 | |
| | R8 | GILLESPIE, et al., Characterization of a Bovine Cone Photoreceptor Phosphodiesterase Purified by Cyclic GMP-Sepharose Chromatography, Journal of Biological Chemistry, vol. 263, no. 17, 1988, pp. 8133-8141 | |
| | R9 | FAWCETT, et al., Molecular Cloning and Characterization of a Distinct Human Phosphodiesterase Gene Family: PDE11A, Proc. Natl. Acad. Sci., vol. 97, no. 7, 2000, pp. 3702-3707 | |
| | R10 | MURASHIMA, et al., Characterization of Particulate Cyclic Nucleotide Phosphodiesterases from Bovine Brain: Purification of a Distinct cGMP-Stimulated Isoenzyme, Biochemistry, vol. 29, no. 22, 1990, pp. 5285-5292 | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Murray/ | Date Considered | 03/17/2008 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------|--------------------------|------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/525,115 |
| | | Filing Date | 18 February 2005 |
| | | First Named Inventor | Hendrix, et al. |
| | | Art Unit | |
| Examiner Name | | | |
| Sheet 3 | of 4 | Attorney Docket Number | LeA 36 230 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | R11 | SODERLING, et al., Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions, Current Opinion in Cell Biology, vol. 12, 2000, pp. 174-179 | |
| | R12 | MIYASHITA, et al., Studies on Pyrazolo[3,4-d]Pyrimidine Derivatives. XVIII. Facile Preparation of 1H-Pyrazolo[3,4-d]Pyrimidin-4(5H)-Ones, Heterocycles, vol. 31, no. 7, 1990, p 1309-1314 | |
| | R13 | SCHMIDT, et al., Heilmittelchemische Studien in der Heterocyclischen Reihe 34. Mitteilung ¹⁾ Pyrazolo-pyrimidine V ²⁾ Eine neue Synthese von Pyrazolo[3,4-d]Pyrimidinen mit coronarerweiternden Eigenschaften, Helvetica Chimica Acta, no. 189, 1962, pp. 1620-1627 | |
| | R14 | LOUGHNEY, et al., Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3',5'-Cyclic Nucleotide Phosphodiesterases, Journal of Biological Chemistry, vol. 271, no. 2, 1996, pp. 796-806 | |
| | R15 | ROSMAN, et al., Isolation and Characterization of Human cDNAs encoding a cGMP-stimulated 3',5'-Cyclic Nucleotide Phosphodiesterase, Gene, vol. 191, 1997, pp. 89-95 | |
| | R16 | MIKI, et al., Characterization of the cDNA and Gene Encoding Human PDE3B, the cGIP1 Isoform of the Human Cyclic GMP-Inhibited Cyclic Nucleotide Phosphodiesterase Family, Genomics, vol. 36, 1996, pp. 476-485 | |
| | R17 | OBERNOLTE, et al., The cDNA of a Human Lymphocyte cyclic-AMP Phosphodiesterase (PDE IV) Reveals a Multigene Family, Gene, vol. 129, 1993 pp. 239-247 | |
| | R18 | LOUGHNEY, et al., Isolation and Characterization of cDNAs encoding PDE5A, a Human cGMP-Binding, cGMP-Specific 3',5'-Cyclic Nucleotide Phosphodiesterase, Gene, vol. 216, 1998, pp. 139-147 | |
| | R19 | HETMAN, et al., Cloning and Characterization of PDE7B, a cAMP-specific Phosphodiesterase, Proc. Natl. Acad. Sci., vol. 97, no. 1, 2000, pp. 472-476 | |
| | R20 | FISHER, et al., Isolation and Characterization of PDE8A, a Novel Human cAMP-Specific Phosphodiesterase, Biochemical and Biophysical Research Communications, vol. 246, 1998, pp. 570-577 | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Murray/ | Date Considered | 03/17/2008 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------|--------------------------|------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/525,115 |
| | | Filing Date | 18 February 2005 |
| | | First Named Inventor | Hendrix, et al. |
| | | Art Unit | |
| Examiner Name | | | |
| Sheet 4 | of 4 | Attorney Docket Number | LeA 36 230 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | R21 | FUJISHIGE, et al., Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A), Journal of Biological Chemistry, vol. 274, no. 26, 1999, pp. 18438-18445 | |
| | R22 | HUETTNER, et al., Primary Culture of Identified Neurons from the Visual Cortex of Postnatal Rats, Journal of Neuroscience, vol. 6, 1986, pp. 3044-3060 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|------------------|-----------------|------------|
| Examiner Signature | /Jeffrey Murray/ | Date Considered | 03/17/2008 |
|--------------------|------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./